Clinically, both CCL22 and CCL17 have been suggested as biomarkers for disease activity in atopic dermatitis (AD), and raised cord blood (CB) levels of CCL22 predict subsequent allergic sensitisation, whilst raised CB CCL17 predicts the later development of allergic symptoms, including asthma53. The gene discussed is CCL17; the disease is atopic eczema.